February 10, 2014
Hisamitsu Pharmaceutical announced on February 5 the results from a PII clinical study of its investigational transdermal Parkinson’s disease treatment HP-3000 (ropinirole HCl) in Japan. In the primary endpoint of efficacy, the compound showed a statistically significant improvement compared to...read more